Paradigm Nears 25% Recruitment Milestone in Pivotal Knee Osteoarthritis Phase 3 Trial

Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an announcement.

Paradigm Biopharmaceuticals has confirmed it has enrolled or randomised enough patients to meet the 25% recruitment threshold in its pivotal global Phase 3 PARA_OA_012 trial of injectable pentosan polysulfate sodium for knee osteoarthritis, with some participants scheduled to begin dosing after the holiday period to safeguard protocol compliance over the six-week regimen. The company reports strong screening activity, boosted by a targeted Medimark-led outreach campaign in Australia that has generated thousands of pre-screened leads, and expects recruitment momentum to accelerate as more sites, including new centres in Moldova and Hong Kong, become fully active, keeping interim analysis timing for mid-2026 and full primary endpoint read-out in late 2026 in line with prior guidance, a key marker for the program’s progress and future commercial prospects.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. is an Australian late-stage drug development company focused on discovering, developing and delivering pharmaceutical therapies that address unmet medical needs. Its current lead program centers on injectable pentosan polysulfate sodium (iPPS), an anti-inflammatory and tissue-regenerative agent being developed for osteoarthritis, particularly knee osteoarthritis, where inflammation plays a major pathogenic role.

YTD Price Performance: -14.67%

Average Trading Volume: 1,161,928

Technical Sentiment Signal: Sell

Current Market Cap: A$137.1M

Learn more about PAR stock on TipRanks’ Stock Analysis page.